Exploring infliximab serum level variability in inflammatory bowel disease: Comprehensive analysis of patient subgroups and treatment outcomes Carles Iniesta-Navalón; Lorena Rentero-Redondo; Rosa Gómez-Espín; Manuel Ríos Saorín; Isabel Nicolás de Prado; Juan José Gascón-Cánovas;

Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study Sandro da Costa Ferreira; Rogério Serafim Parra; Ligia Yukie Sassaki; José Miguel Luz Parente; Munique Kurtz de Mello; Liliana Andrade Chebli; Rafael Luís Luporini; Antonio José Tiburcio Alves Junior; Fernando Jorge Firmino Nóbrega; Bruno César da Silva; Eron Fábio Miranda; Abel Botelho Quaresma; Guilherme Mattioli Nicollelli; Rodrigo Galhardi Gasparini; Renata de Medeiros Dutra; Juarez Roberto de Oliveira Vasconcelos; Katia da Conceição da Silva; Daniéla Oliveira Magro; Marcello Rabello Imbrizi; Cristiane Kibune Nagasako; Omar Féres; Luiz Ernesto de Almeida Troncon; Paulo Gustavo Kotze; Júlio Maria Fonseca Chebli;

Perception of the impact of intravenous biological treatment on the work and professional environment in patients with inflammatory bowel disease Carlos González-Muñoza; Cristina Gely; Jordi Gordillo; Margalida Calafat; Federico Bertoletti; Fiorella Cañete; Míriam Mañosa; Alberto López-Faba; Paola Torres; Eugeni Domènech; Esther Garcia-Planella;